Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Gabe Fernandez who wrote (714)	5/4/1998 9:16:00 PM
From: yosi s	Read Replies (1) \| Respond to of 1491

Glad to see neurosurgeon on the thread. did you get a chance to see PARS web page. The give mortality rate for the total group. And yes if the placebo group mortality rate is as expected, then we got a winner. Other wise we got to explain how come placebo doing so well. As far as their version of taxoxiphen in animal model they saw tumeur shrinking , much more then seen with tamoxiphen alone. They are setting now for phase 1 study. Hopefully now with stream of revenues, they will be able to manage it well and the private placement is last of its kind . + way ahead.